International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors

Pharmacological Reviews

Volumn 53, Issue 4, 2001, Pages 527-552

  Fredholm, B B ^a   Ijzerman, A P ^a   Jacobson, K A ^a   Klotz, K N ^a   Linden, J ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL CELL; BINDING SITE; CELL PROLIFERATION; ENZYME ACTIVATION; GENE STRUCTURE; HUMAN; HUMAN CELL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; RECEPTOR UPREGULATION; REVIEW; SECOND MESSENGER; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; SPECIES DIFFERENTIATION;

ANIMALS; HUMANS; PHARMACOLOGY; RECEPTORS, PURINERGIC P1; SIGNAL TRANSDUCTION; TERMINOLOGY;

EID: 0035209620     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (360)

1. Modulation of apoptosis by adenosine in the central nervous system: A possible role for the A3 receptor. Pathophysiological significance and therapeutic implications for neurodegenerative disorders
2. 1 receptor agonism in the immature rat brain and heart
3. Maternal caffeine intake has minor effects on adenosine receptor ontogeny in the rat brain
4. A single species of A1 adenosine receptor expressed in Chinese hamster ovary cells not only inhibits cAMP accumulation but also stimulates phospholipase C and arachidonate release
5. Adenosine receptor-induced cAMP changes in D384 astrocytoma cells and the effect of bradykinin thereon
6. Bradykinin inhibition of cyclic AMP accumulation in D384 astrocytoma cells. Evidence against a role of cyclic GMP
7. Bradykinin inhibits cyclic AMP accumulation in D384-human astrocytoma cells via a calcium-dependent inhibition of adenylyl cyclase
8. Demonstration of the existence of mRNAs encoding N1/cif and N2/cit sodium/nucleoside cotransporters in rat brain
9. The control of the metabolism and the hormonal role of adenosine
10. 2A receptors on nerve growth factor-induced phosphorylation of extracellular regulated kinases 1/2 in PC12 cells
11. 2A receptors upon NGF-induced differentiation of PC12 cells
12. Cloning, characterisation and chromosomal assignment of the human adenosine A3 receptor (ADORA3) gene
13. 1 receptors, KATP channels, and ischemic preconditioning in dogs
14. Canine mast cell adenosine receptors: Cloning and expression of the A3 receptor and evidence that degranulation is mediated by the A2B receptor
15. Differential A(1)-adenosine receptor reserve for inhibition of cyclic AMP accumulation and G-protein activation in DDT(1) MF-2 cells
16. An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors
17. Nucleoside transporters: Molecular biology and implications for therapeutic development
18. Striatal adenosine levels measured in vivo by microdialysis in rats with unilateral dopamine denervation
19. 2-bradykinin receptor linked to phospholipase C and inhibition of dopamine stimulated cyclic AMP accumulation in the human astrocytoma cell line D384
20. A(3) adenosine receptor ligands: History and perspectives
21. 2A adenosine receptor antagonists
22. Synthesis and biological effects of a new series of 2-amino-3-benzoylthiophenes as allosteric enhancers of A1-adenosine receptor
23. Site-directed mutagenesis of the human A1 adenosine receptor: Influences of acidic and hydroxy residues in the first four transmembrane domains on ligand binding
24. Release of adenosine from ischemic brain
25. Dopamine and glutamate agonists stimulate neuron-specific expression of Fos-like protein in the striatum
26. Why are A(2B) receptors low-affinity adenosine receptors? Mutation of Asn273 to Tyr increases affinity of human A(2B.) receptor for 2-(1-hexynyl)adenosine
27. Cloning of an adenosine A1 receptor-encoding gene from rabbit
28. The phosphoprotein DARPP-32 mediates cAMP-dependent potentiation of striatal N-methyl-D-aspartate responses
29. A common mechanism mediates long-term changes in synaptic transmission after chronic cocaine and morphine
30. N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor
31. Regional and subcellular distribution of Sadenosylhomocysteine hydrolase in the adult rat brain
32. Abolished tubuloglomerular feedback and increased plasma renin in adenosine A(1) receptor-deficient mice
33. The role of cyclic AMP as a precursor of extracellular adenosine in the rat hippocampus
34. Modulation of excitatory synaptic transmission by adenosine released from single hippocampal pyramidal neurons
35. Adenosine receptor activation in human fibroblasts: Nucleoside agonists and antagonists
36. Adenosine antagonism by purines, pteridines and benzopteridines in human fibroblasts
37. Adenosine receptors in brain membranes: Binding of N6-cyclohexyl-[3H]-adenosine and 1,3-diethyl-8-[3H]-phenylxanthine
38. Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes
39. 3H]-NECA in rat striatal membranes
40. A basis for distinguishing two types of purinergic receptor
41. Adenosine receptor agonists: Synthesis and biological evaluation of the diastereoisomers of 2-(3-hydroxy-3-phenyl-1-propyn-1-yl)NECA
42. Kainate-evoked release of adenosine from the hippocampus of the anaesthetised rat: Possible involvement of free radicals
43. Preactivation permits subsequent stimulation of phospholipase C by G(i)-coupled receptors
44. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice
45. The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice
46. Release of endogenous adenosine and its metabolites by the activation of NMDA receptors in the rat hippocampus in vivo
47. Regulation of adenylyl cyclase type VI activity during desensitization of the A2a adenosine receptor-mediated cyclic AMP response: Role for protein phosphatase 2A
48. Multiple mechanisms for desensitization of A2a adenosine receptor-mediated cAMP elevation in rat pheochromocytoma PC12 cells
49. Characterization of the rat A2a adenosine receptor gene
50. Ligand-induced phosphorylation, clustering, and desensitization of A1 adenosine receptors
51. Studies on the coronary dilator actions of some adenosine analogues
52. Adenosine relaxes the aorta by interacting with an A2 receptor and an intracellular site
53. Netrin-1-mediated axon outgrowth and cAMP production requires interaction with adenosine A2b receptor
54. Galpha(olf) is necessary for coupling D1 and A2a receptors to adenylyl cyclase in the striatum
55. 2a adenosine receptor agonists
56. 2-Alkynyl derivatives of adenosine and adenosine-5′-N-ethyluronamide as selective agonists at A2 adenosine receptors
57. Adenosine, an endogenous anti-inflammatory agent
58. 2A receptors
59. Inhaled adenosine and guanosine on airway resistance in normal and asthmatic subjects
60. Thermodynamics of full agonist, partial agonist, and antagonist binding to wild-type and mutant adenosine A1 receptors
61. Structure-activity relationships for N6-substituted adenosines at a brain A1-adenosine receptor with a comparison to an A2-adenosine receptor regulating coronary blood flow
62. Adenosine A(1) receptor activation induces delayed preconditioning in rats mediated by manganese superoxide dismutase
63. Signal characteristics of G protein-transactivated EGF receptor
64. Effects of caffeine on mammalian atrial muscle, and its interaction with adenosine and calcium
65. Adenosine inhibits the NMDA receptor mediated excitatory postsynaptic potential in the hippocampus
66. 1 receptor activation
67. Adenosine-an endogenous neuroprotective metabolite and neuromodulator
68. Human adenosine A2a receptor (A2aAR) gene: Systematic mutation screening in patients with schizophrenia
69. Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release
70. Levels of endogenous adenosine in rat striatum. II. Regulation of basal and N-methyl-D-aspartate-induced levels by inhibitors of adenosine transport and metabolism
71. Levels of endogenous adenosine in rat striatum. I. Regulation by ionotropic glutamate receptors, nitric oxide and free radicals
72. Human adenosine A1 receptor and P2Y2-purinoceptor-mediated activation of the mitogen-activated protein kinase cascade in transfected CHO cells
73. 1 MF-2: The role of protein kinase C
74. Involvement of G-protein betagamma subunits in coupling the adenosine A1 receptor to phospholipase C in transfected CHO cells
75. 2H]-SCH 58261
76. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart
77. Adenosine inhibits growth of human aortic smooth muscle cells via A2B receptors
78. 2b receptor
79. A(2B) receptors mediate antimitogenesis in vascular smooth muscle cells
80. Regulation of extracellular adenosine in rat hippocampal slices is temperature dependent: Role of adenosine transporters
81. Adenine nucleotides undergo rapid, quantitative conversion to adenosine in the extracellular space in rat hippocampus
82. Activation of hippocampal adenosine A3 receptors produces a desensitization of A1 receptor-mediated responses in rat hippocampus
83. Adenosine neuromodulation
84. 1 receptor knockout mice
85. The stimulant effects of caffeine on locomotor behavior in mice are mediated through its blockade of adenosine A(2A) receptors
86. Release of adenosine from rat hippocampal slices by nitric oxide donors
87. cAMP and beta gamma subunits of heterotrimeric G proteins stimulate the mitogen-activated protein kinase pathway in COS-7 cells
88. Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma
89. Role of p38 mitogen-activated protein kinase and extracellular signal-regulated protein kinase kinase in adenosine A2B receptor-mediated interleukin-8 production in human mast cells
90. Evolving concepts in G protein-coupled receptor endocytosis: The role in receptor desensitization and signaling
91. Adaptive changes in adenosine receptors following long term treatment with the adenosine receptor agonist R-phenylisopropyl adenosine
92. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia
93. Antagonistic interaction between adenosine A2A receptors and dopamine D2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia
94. 1 receptors
95. 1 receptors in stably cotransfected fibroblast cells
96. 2 receptors in rat striatal membranes
97. 2 dopamine receptors in rat striatum
98. 2-Chloroadenosine attenuates NMDA, kainate, and quisqualate toxicity
99. Adenosine release in the ventral striatum of the rat is modulated by endogenous nitric oxide
100. Adenosine acts as a chemoprotective agent by stimulating G-CSF production: A role for A1 and A3 adenosine receptors
101. Adenosine acts as an inhibitor of lymphoma cell growth: A major role for the A3 adenosine receptor
102. Mast cell degranulation following adenosine A3 receptor activation in rats
103. Effect of adenosine, adenosine analogues and drugs inhibiting adenosine inactivation on lipolysis in rat fat cells
104. Adenosine actions and adenosine receptors after 1 week treatment with caffeine
105. Adenosine and neuroprotection
106. Purines and neutrophil leukocytes
107. Nomenclature and classification of purinoceptors
108. Towards a revised nomenclature for P1 and P2 receptors
109. Structure and function of adenosine receptors and their genes
110. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use
111. How does adenosine inhibit transmitter release?
112. Effect of some phosphodiesterase inhibitors on central dopamine mechanisms
113. Modulation of neurotransmission by purine nucleotides and nucleosides
114. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells
115. The adenosine receptor mediated accumulation of cyclic AMP in Jurkat cells is enhanced by a lectin and by phorbol esters
116. α-adrenoceptor stimulation, but not muscarinic stimulation, increases cyclic AMP accumulation in brain slices due to protein kinase C mediated enhancement of adenosine receptor effects
117. Propentofylline and other adenosine transport inhibitors increase the efflux of adenosine following electrical or metabolic stimulation of rat hippocampal slices
118. Xanthine derivatives as adenosine receptor antagonists
119. Adenosine A2A receptors mediate the inhibitory effect of adenosine on formyl-Met-Leu-Phe-stimulated respiratory burst in neutrophil leukocytes
120. Interactions of purified bovine brain A1-adenosine receptors with G-proteins. Reciprocal modulation of agonist and antagonist binding
121. A1 adenosine receptors expressed in CHO-cells couple to adenylyl cyclase and to phospholipase C
122. Molecular characterization of a human brain adenosine A2 receptor
123. Structure activity relationships of N6-benzyladenosine-5′-uronamides as A3-selective adenosine agonists
124. A2B adenosine and P2Y2 receptors stimulate mitogen-activated protein kinase in human embryonic kidney-293 cells. Cross-talk between cyclic AMP and protein kinase C pathways
125. A(3) adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis
126. Site-directed mutagenesis studies of human A(2A) adenosine receptors: Involvement of glu(13) and his(278) in ligand binding and sodium modulation
127. Differential expression of a(2a), A(1)-adenosine and D(2)-dopamine receptor genes in rat peripheral arterial chemoreceptors during postnatal development
128. Glucocorticoid receptor activation leads to up-regulation of adenosine A1 receptors and down-regulation of adenosine A2 responses in DDT1 MF-2 smooth muscle cells
129. ATP and its metabolite adenosine act synergistically to mobilize intracellular calcium via the formation of inositol 1,4,5-trisphosphate in a smooth muscle cell line
130. Stimulation of adenosine A1 receptors and bradykinin receptors, which act via different G-proteins, synergistically raises inositol 1,4,5-trisphosphate and intracellular free calcium in DDT1 MF-2 smooth muscle cells
131. Activation of adenosine A1 and bradykinin receptors increases protein kinase C and phospholipase D activity in smooth muscle cells
132. Activation of phospholipase C and phospholipase D by stimulation of adenosine A1, bradykinin or P2U receptors does not correlate well with protein kinase C activation
133. Adenosine receptor down-regulation and insulin resistance following prolonged incubation of adipocytes with an A1 adenosine receptor agonist
134. Down-regulation of Gi sub-types by prolonged incubation of adipocytes with an A1 adenosine receptor agonist
135. Functional and structural complexity of signal transduction via G-protein-coupled receptors
136. The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades
137. Lack of tolerance to motor stimulant effects of a selective adenosine A2A receptor antagonist
138. Activation of NMDA receptors induces dephosphorylation of DARPP-32 in rat striatal slices
139. A postsynaptic interaction between dopamine D1 and NMDA receptors promotes presynaptic inhibition in the rat nucleus accumbens via adenosine release
140. 5-(N-ethylcarboxamido)adenosine desensitizes the A2b-adenosine receptor in lung circulation
141. Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy
142. Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum
143. Cyclopentyladenosine-induced homologous down-regulation of A1 adenosine receptors (A1AR) in intact neurons is accompanied by receptor sequestration but not a reduction in A1AR mRNA expression or G protein alpha-subunit content
144. Three-dimensional models of neurotransmitter G-binding protein-coupled receptors
145. Cloning, expression and pharmacological characterization of rabbit adenosine A1 and A3 receptors
146. Functional coupling of adenosine A2a receptor to inhibition of the mitogen-activated protein kinase cascade in Chinese hamster ovary cells
147. A comparison of N-methyl-D-aspartate-evoked release of adenosine and [3H]norepinephrine from rat cortical slices
148. Re-evaluation of bacteriorhodopsin as a model for G protein-coupled receptors
149. An activator of protein kinase C (phorbol-12-myristate-13-acetate) augments 2-chloroadenosine-elicited accumulation of cyclic AMP in guinea pig cerebral cortical particulate preparations
150. Extracellular adenosine levels in neostriatum and hippocampus druing rest and activity periods of rats
151. CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity
152. Molecular modeling of adenosine receptors. The ligand binding site on the rat adenosine A2A receptor
153. Molecular modeling of adenosine receptors. I. The ligand binding site of the A1 receptor
154. Site-directed mutagenesis of the human adenosine A2A receptor. Critical involvement of Glu13 in agonist recognition
155. Adenosine receptors in neurological disorders
156. 1,3-Dialkylxanthine derivatives having high potency as antagonists at human A2B adenosine receptors
157. [3H]xanthine amine congener of 1,3-dipropyl-8-phenylxanthine: An antagonist radioligand for adenosine receptors
158. Adenosine analogs with covalently attached lipids have enhanced potency at A1-adenosine receptors
159. Cloning and chromosomal localization of the human A2b adenosine receptor gene (ADORA2B) and its pseudogene
160. [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain
161. Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors
162. Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition
163. Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation
164. Species difference in the G protein selectivity of the human and bovine A1-adenosine receptor
165. Effect of long term caffeine treatment on A1 and A2 adenosine receptor binding and on mRNA levels in rat brain
166. 3H]CGS 21680 to rat brain using autoradiography
167. 3H]CGS 21680 to rat cortex differs from its binding to rat striatum
168. Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor
169. Release of purines, noradrenaline and GABA from rat hippocampal slices by field stimulation
170. Adenosine receptor-mediated changes in cyclic AMP production and DNA synthesis in cultured arterial smooth muscle cells
171. A(3) adenosine receptor activation attenuates neutrophil function and neutrophil-mediated reperfusion injury
172. Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence
173. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys
174. D1 dopamine receptor-mediated induction of zif268 and c-fos in the dopamine-depleted striatum: Differential regulation and independence from NMDA receptors
175. Agonist-receptor efficacy I: Mechanisms of efficacy and receptor promiscuity
176. Covalent modification of transmembrane span III of the A1 adenosine receptor with an antagonist photoaffinity probe
177. 2-Substitution of N6-benzyladenosine-5′-uronamides enhances selectivity for A3 adenosine receptors
178. Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition
179. Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor
180. Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors
181. Surface of bacteriorhodopsin revealed by high-resolution electron crystallography
182. 2-Substituted N-ethylcarboxamidoadenosine derivatives as high-affinity agonists at human A3 adenosine receptors
183. Photoaffinity labeling of A1-adenosine receptors
184. Comparative pharmacology of human adenosine receptor subtypes - Characterization of stably transfected receptors in CHO cells
185. Effector coupling of human A3 adenosine receptors
186. Comparison of A1 adenosine receptors in brain from different species by radioligand binding and photoaffinity labeling
187. Chronic hypoxia reduces adenosine A2A receptor-mediated inhibition of calcium current in rat PC12 cells via downregulation of protein kinase A
188. Amphetamine and dopamine-induced immediate early gene expression in striatal neurons depends on postsynaptic NMDA receptors and calcium
189. Patterns of A2A extracellular adenosine receptor expression in different functional subsets of human peripheral T cells. Flow cytometry studies with anti-A2A receptor monoclonal antibodies
190. The role of receptor kinases and arrestins in G protein-coupled receptor regulation
191. 2A receptors
192. olf in rat striatum
193. 2A receptors in human brain
194. CD3/T-cell receptor coupling to a pertussis and cholera toxin-insensitive G-protein
195. Activated cardiac adenosine A(1) receptors translocate out of caveolae
196. 1 receptor mediated protection of the globally ischemic isolated rat heart
197. Extracellular adenosine concentrations during in vitro ischemia in rat hippocampal slices
198. Characterization and chromosomal localization of the human A2a adenosine receptor gene: ADORA2A
199. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2A receptor
200. G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization
201. Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2, 4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists
202. Selective amplification and cloning of four new members of the G protein-coupled receptor family
203. The orphan receptor cDNA RDC7 encodes an A1 adenosine receptor
204. Cloning and functional characterization of a human A1 adenosine receptor
205. Cloned adenosine A3 receptors: Pharmacological properties, species differences and receptor functions
206. Allosteric enhancement of adenosine receptors
207. Molecular approach to adenosine receptors: Receptor-mediated mechanisms of tissue protection
208. Molecular cloning and functional expression of a sheep A3 adenosine receptor with widespread tissue distribution
209. Characterization of human A(2B) adenosine receptors: Radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells
210. 3H]-CGS 21680 in the rat brain
211. Involvement of adenosine deaminase and adenosine kinase in regulating extracellular adenosine concentration in rat hippocampal slices
212. Intracellular formation and release of adenosine from rat hippocampal slices evoked by electrical stimulation and energy depletion
213. 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX) - A selective high affinity antagonist radioligand for A1 adenosine receptors
214. 2-Chloro-N6-cyclopentyladenosine: A highly selective agonist at A1 adenosine receptors
215. Subclasses of external adenosine receptors
216. Adenosine analogs inhibit adipocyte adenylate cyclase by a GTP-dependent process: Basis for actions of adenosine and methylxanthines on cyclic AMP production and lipolysis
217. Subclasses of external adenosine receptors
218. Modification of the rat adipocyte A1 adenosine receptor-adenylate cyclase system during chronic exposure to an A1 adenosine receptor agonist: Alterations in the quantity of Gs alpha and Gi alpha are not associated with changes in their mRNAs
219. Structure of bacteriorhodopsin at 1.55 A resolution
220. Regulation of tyrosine kinase cascades by G-protein-coupled receptors
221. Mapping of a human A2a adenosine receptor (ADORA2) to chromosome 22
222. Species differences in brain adenosine A1 receptor pharmacology revealed by use of xanthine and pyrazolopyridine based antagonists
223. RDC8 codes for an adenosine A2 receptor with physiological constitutive activity
224. Release of adenosine by activation of NMDA receptors in the hippocampus
225. Adenosinergic approaches to stroke therapeutics
226. 1 receptor in vivo
227. High-performance liquid chromatography of the adenosine A1 agonist N6-cyclopentyladenosine and the A1 antagonist 8-cyclopentyltheophylline and its application in a pharmacokinetic study in rats
228. Antibodies to an epitope on synapsin I detect a protein associated with the endocytic compartment in non-neuronal cells
229. The G protein beta subunit is a determinant in the coupling of the Gs alpha subunit to the beta adrenergic and A2a adenosine receptors
230. 2a adenosine receptor from guinea pig brain
231. Molecular cloning of a novel putative G-protein coupled receptor expressed during rat spermiogenesis
232. Localization and functional effects of adenosine A1 receptors on cardiac vagal afferents in adult rats
233. Evidence for co-expression and desensitization of A2a and A2b adenosine receptors in NG108-15 cells
234. Mitogenic signaling from P1 and P2 purinergic receptors to mitogen-activated protein kinase in human fetal astrocyte cultures
235. Phorbol-12,13-dibutyrate enhances the cyclic AMP accumulation in rat hippocampal slices induced by adenosine analogues
236. Activation of protein kinase C inhibits prostaglandin- and potentiates adenosine receptor-stimulated accumulation of cyclic AMP in human T-cell leukemia line
237. Dual effects of protein kinase-C on receptor-stimulated cAMP accumulation in a human T-cell leukemia line
238. G alpha 15 and G alpha 16 couple a wide variety of receptors to phospholipase C
239. A(2A) adenosine receptor-mediated inhibition of renal injury and neutrophil adhesion
240. Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney
241. Identification of A2a adenosine receptor domains involved in selective coupling to Gs. Analysis of chimeric A1/A2a adenosine receptors
242. 125I-4-aminobenzyl-5′-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor
243. Cloning, expression, and characterization of the unique bovine A1 adenosine receptor. Studies on the ligand binding site by site-directed mutagenesis
244. The role of receptor structure in determining adenosine receptor activity
245. Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors
246. Pharmacology of adenosine A2A receptors
247. Crystal structure of rhodopsin: A G protein-coupled receptor
248. 3 adenosine receptor
249. Differential interaction with and regulation of multiple G-proteins by the rat A3 adenosine receptor
250. Identification of an A2a adenosine receptor domain specifically responsible for mediating short-term desensitization
251. Identification of threonine residues controlling the agonist-dependent phosphorylation and desensitization of the rat A(3) adenosine receptor
252. Processing of adenosine receptor agonists in rat and human whole blood
253. Endogenous adenosine release from hippocampal slices: Excitatory amino acid agonists stimulate release, antagonists reduce the electrically-evoked release
254. Protein kinase C regulates adenosine A2a receptor mRNA expression in SH-SY5Y cells
255. 2a adenosine receptor gene
256. Agonist-induced desensitization of A2B adenosine receptors
257. 2b receptors from human brain
258. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats
259. G protein-coupled receptor kinases
260. Adenosine and glutamate modulate each other's release from rat hippocampal synaptosomes
261. Stimulation of adenosine A1 receptors prevents the EEG arousal due to dopamine D1 receptor activation in rabbits
262. Effects of Sch 58261, an adenosine A(2A) receptor antagonist, on quinpirole-induced turning in 6-hydroxydopamine-lesioned rats. Lack of tolerance after chronic caffeine intake
263. Adenosine: A mediator of the sleep-inducing effects of prolonged wakefulness
264. 2a selective adenosine receptor antagonist
265. Metabolism of [14C]-adenine and derivatives by cerebral tissues, superfused and electrically stimulated
266. Crosstalk between Galpha(i)- and Galpha(q)-coupled receptors is mediated by Gbetagamma exchange
267. Cardiovascular and metabolic actions of adenosine and adenosine analogs
268. 1 MF-2 cells
269. The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells
270. Separate promoters in the human A1 adenosine receptor gene direct the synthesis of distinct messenger RNAs that regulate receptor abundance
271. Dexamethasone stimulates human A1 adenosine receptor (A1AR) gene expression through multiple regulatory sites in promoter B
272. 1 adenosine receptor gene
273. Design, synthesis, and evaluation of novel adenosine A2A receptor agonists
274. Adenosine A2A agonists: A potential new type of atypical antipsychotic
275. Identification of the adenine binding site of the human A1 adenosine receptor
276. Characterization of the murine A1 adenosine receptor promoter, potent regulation by GATA-4 and Nkx2.5
277. Molecular characterization of recombinant human adenosine receptors
278. N6, C8-distributed adenosine derivatives as partial agonists for adenosine A1 receptors
279. Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system
280. Selective adenosine-A2A activation reduces lung reperfusion injury following transplantation
281. Adenosine and brain ischemia
282. Neuroprotective role of adenosine in cerebral ischemia
283. cDNA cloning and characterization of A3i, an alternatively spliced rat A3 adenosine receptor variant
284. 3 adenosine receptor
285. Distinct roles for recombinant cytosolic 5′-nucleotidase-I and -II in AMP and IMP catabolism in COS-7 and H9c2 rat myoblast cell lines
286. The mechanism of adenosine formation in cells. Cloning of cytosolic 5′-nucleotidase-I
287. Molecular cloning and characterization of the human A3 adenosine receptor
288. Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells
289. Adenosine primes the opening of mitochondrial ATP-sensitive potassium channels: A key step in ischemic preconditioning?
290. The effect of adenosine and adenine nucleotides on the cyclic adenosine 3′, 5′ phosphate content of guinea pig cerebral cortex slices
291. Watersoluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists
292. Targeting of G protein coupled receptors to the basolateral surface of polarized renal epithelial cells involves multiple, non-contiguous structural signals
293. Receptors coupled to pertussis toxin-sensitive G-proteins traffic to opposite surfaces in Madin-Darby canine kidney cells. A1 adenosine receptors achieve apical and alpha 2A adrenergic receptors achieve basolateral localization
294. Disruption of microtubules reveals two independent apical targeting mechanisms for G-protein-coupled receptors in polarized renal epithelial cells
295. 1 adenosine receptors in pig brain cortical membranes
296. Adenosine deaminase and A1 adenosine receptors internalize together following agonist-induced receptor desensitization
297. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: An in situ hybridization histochemistry study
298. Serine and alanine mutagenesis of the nine native cysteine residues of the human A(1) adenosine receptor
299. Correlation of 5′-nucleotidase activity and selective transneuronal transfer of adenosine in the hippocampus
300. 3 receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1/2
301. Characterization of adenosine receptors in rat brain by (-)[3H]-N6-phenylisopropyladenosine
302. The Mapk signaling cascade
303. Activation of mitogen-activated protein kinase by the A(2A)-adenosine receptor via a rap1-dependent and via a p21(ras)-dependent pathway
304. Stimulation of the mitogen-activated protein kinase via the A2A-adenosine receptor in primary human endothelial cells
305. Adenosine A partial agonist of the growth hormone secretagogue receptor
306. A T1083C polymorphism in the human adenosine A2a receptor gene is not associated with essential hypertension
307. Cloning of human adenosine kinase cDNA: Sequence similarity to microbial ribokinases and fructokinases
308. Molecular cloning and expression of the cDNA for a novel A2-adenosine receptor subtype
309. Binding of Dcc by netrin-1 to mediate axon guidance independent of adenosine A2B receptor activation
310. Regulation of mitogen-activated protein kinase cascades in the heart
311. Cyclic Amp-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A2A receptor agonists
312. Meditation of tubuloglomerular feedback by adenosine: Evidence from mice lacking adenosine 1 receptors
313. Opposite tonic modulation of dopamine and adenosine on c-fos mRNA expression in striatopallidal neurons
314. Glucocorticoids regulate the expression of adenosine A1 but not A2A receptors in rat brain
315. Distribution, biochemistry and function of striatal adenosine A2A receptors
316. Cellular expression of adenosine A2A receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas
317. Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2 and adenosine A2A receptors
318. Activation of adenosine A2A and dopamine D1 receptors stimulates cyclic AMP-dependent phosphorylation of DARPP-32 in distinct populations of striatal projection neurons
319. Regional differences in the ability of caffeine to affect haloperidol-induced striatal c-fos mRNA expression in the rat
320. Biphasic changes in locomotor behavior and in expression of mRNA for NGFI-A and NGFI-B in rat striatum following acute caffeine administration
321. The stimulatory action and the development of tolerance to caffeine is associated with alterations in gene expression in specific brain regions
322. Adenosine A1 receptors are located predominantly on axons in the rat hippocampal formation
323. Adenosine and inosine increase cutaneous vasopermeability by activating A(3) receptors on mast cells
324. Neuronal release of soluble nucleotidases and their role in neurotransmitter inactivation
325. A threonine residue in the seventh transmembrane domain of the human A1 adenosine receptor mediates specific agonist binding
326. Molecular cloning and characterization of a human brain A1 adenosine receptor cDNA
327. N6-bicycloalkyladenosines with unusually high potency and selectivity for the adenosine A1 receptor
328. Dominance of Gs in doubly Gs/Gi-coupled chimeric A1/A2A adenosine receptors in HEK-293 cells
329. Cloning and expression of a bovine adenosine A1 receptor cDNA
330. A1 adenosine receptors. Two amino acids are responsible for species differences in ligand recognition
331. Adenosine is an agonist of the growth hormone secretagogue receptor
332. Arrangement of rhodopsin transmembrane alpha-helices
333. Adenosine inhibits the accumulation of cyclic AMP in cultured brain cells
334. Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells
335. Allosteric modulation of the adenosine A(1) receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding
336. 5′-substituted adenosine analogs as new high-affinity partial agonists for the adenosine A1 receptor
337. A binding site model and structure-activity relationships for the rat A2 adenosine receptor
338. A novel class of adenosine A3 receptor ligands. 2. Structure affinity profile of a series of isoquinoline and quinazoline compounds
339. Isoquinoline and quinazoline urea analogues as antagonists for the human adenosine A(3) receptor
340. Molecular architecture of G protein-coupled receptors
341. Hemodynamic effects and histamine release elicited by the selective adenosine A3 receptor agonist 2-Cl-IB-MECA in conscious rats
342. Selectivity of action of 8-alkylamino analogues of N6-cyclopentyladenosine in vivo: Hemodynamic versus anti-lipolytic responses in rats
343. Stereospecificity in some central and circulatory effects of phenylisopropyl-adenosine (PIA)
344. [(3)H]MRE 3008F20 a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors
345. Comparison between theophylline and an adenosine non-blocking xanthine in acute asthma
346. Biochemical characterization of the triazoloquinazoline, CGS 15943, a novel, non-xanthine adenosine antagonist
347. Multiple sodium-dependent nucleoside transport systems in bovine renal brush-border membrane vesicles
348. Brain adenosine concentration during hypoxia in rat
349. MK-801 prevents alterations in the mesoaccumbens dopamine system associated with behavioral sensitization to amphetamine
350. Trafficking itineraries of G protein-coupled receptors in epithelial cells do not predict receptor localization in neurons
351. Phosphorylation of the G protein gamma12 subunit regulates effector specificity
352. Role of the prenyl group on the G protein gamma subunit in coupling trimeric G proteins to A1 adenosine receptors
353. Functional uncoupling of adenosine A2A receptors and reduced response to caffeine in mice lacking dopamine D2 receptors
354. Purine levels in the intact rat brain. Studies with an implanted perfused hollow fiber
355. Characterization of the mouse A3 adenosine receptor gene: Exon/intron organization and promoter activity
356. A role for the A3 adenosine receptor in determining tissue levels of cAMP and blood pressure: Studies in knock-out mice
357. Molecular cloning and characterization of an adenosine receptor: The A3 adenosine receptor
358. Extracellular metabolism of ATP and other nucleotides
359. New insights into molecular structure and function of ectonucleotidases in the nervous system